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Abstract
Background: Evidence on the effectiveness of intra-articular corticosteroid injection for hip osteoarthritis is limited
and conflicting. The primary objective of the Hip Injection Trial (HIT) is to compare pain intensity over 6 months, in
people with hip OA between those receiving an ultrasound-guided intra-articular hip injection of corticosteroid
with 1% lidocaine hydrochloride plus best current treatment with those receiving best current treatment alone.
Secondary objectives are to determine specified comparative clinical and cost-effectiveness outcomes, and to
explore, in a linked qualitative study, the lived experiences of patients with hip OA and experiences and impact of,
ultrasound-guided intra-articular hip injection.
Methods: The HIT trial is a pragmatic, three-parallel group, single-blind, superiority, randomised controlled trial in
patients with painful hip OA with a linked qualitative study. The current protocol is described, in addition to details and
rationale for amendments since trial registration. 204 patients with moderate-to-severe hip OA will be recruited.
Participants are randomised on an equal basis (1:1:1 ratio) to one of three interventions: (1) best current treatment, (2)
best current treatment plus ultrasound-guided intra-articular hip injection of corticosteroid (triamcinolone acetonide
40 mg) with 1% lidocaine hydrochloride, or (3) best current treatment plus an ultrasound-guided intra-articular hip
injection of 1% lidocaine hydrochloride alone. The primary endpoint is patient-reported hip pain intensity across
2 weeks, 2 months, 4 months and 6 months post-randomisation. Recruitment is over 29 months with a 6-month
follow-up period. To address the primary objective, the analysis will compare participants’ ‘average’ follow-up pain NRS
scores, based on a random effects linear repeated-measures model. Data on adverse events are collected and reported
in accordance with national guidance and reviewed by external monitoring committees. Individual semi-structured
interviews are being conducted with up to 30 trial participants across all three arms of the trial.
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Discussion: To ensure healthcare services improve outcomes for patients, we need to ensure there is a robust and
appropriate evidence-base to support clinical decision making. The HIT trial will answer important questions regarding
the clinical and cost-effectiveness of intra-articular corticosteroid injections.
Trial registration: ISRCTN: 50550256, 28th July 2015.
Background
Hip osteoarthritis affects a substantial, and growing,
number of people worldwide. Its incidence and preva-
lence are increasing due to ageing and obesity. It is esti-
mated that between 10 and 18% of those aged over
60 years are affected, rising to one in three patients over
the age of 85 years [1], with a substantial proportion ex-
periencing persistent pain, loss of function and decline
in health-related quality of life [2].
In 2016, in the United Kingdom (UK), an estimated
92,465 primary total hip replacement (THR) operations
were carried out, with approximately 90% being per-
formed for OA [3]. Whilst not all patients with hip osteo-
arthritis will need a THR, the numbers of THR are
continuing to rise [4, 5]. Patients with hip OA are typically
treated in primary care for several years before referral for
surgical opinion, with evidence suggesting that primary
care management is suboptimal and that patients with hip
pain feel their pain is neglected despite consulting their
general practitioner (GP) [6]. In one observational study
from the Netherlands, patients with incident hip OA
remained under GP care for an average of 7 years
(82 months) before referral to orthopaedics, suggesting
that a considerable period of time is available to help
patients through the application of non-surgical inter-
ventions before surgery is suggested as an option [7].
This is important, as non-surgical interventions could
significantly contribute to postponing hip replacement
[8], which in turn can delay or prevent future revision
surgery.
A range of treatments, including analgesia and exercise
therapy, are available to help people with hip OA, al-
though the evidence supporting their use, especially in
primary care settings, is limited. Influential organisations
including the European League Against Rheumatism
(EULAR), Arthritis Research UK and the National Insti-
tute for Health and Care Excellence (NICE) highlight
the lack of evidence from randomised controlled trials
(RCTs) conducted exclusively with people with hip OA
[9, 10]. NICE guidance for the non-surgical treatment of
OA advises a combination of non-pharmacological and
pharmacological treatments, with education, exercise
and weight reduction being core treatments [9]. Options
for analgesia include paracetamol, oral non-steroidal
anti-inflammatory drugs (NSAIDs) and opiates, with
intra-articular corticosteroid injection recommended as
an adjunct for those with moderate-severe pain.
Intra-articular corticosteroid injection is not used to
treat patients with hip OA as widely as it could be in the
UK owing to a lack of local availability and uncertainties
about patient selection and potential benefit [11].
Intra-articular hip injection is typically administered
using imaging guidance, either fluoroscopy or ultra-
sound, to improve the accuracy of the injection [12].
The evidence supporting the use of intra-articular
corticosteroid injection for hip OA is limited and con-
flicting. Of the five published RCTs of intra-articular
corticosteroid injection for hip OA [11, 13–16], all
recruited small numbers of participants from secondary
care (≤40 per treatment group) and employed
short-term follow-up (maximum three months).
Whereas two RCTs with hip OA patients have dem-
onstrated clinical benefits at eight weeks post-injection
[11, 16] and two at three months [14, 16], one reported
no significant difference in pain or function at three
months [15]. There is evidence that beneficial effects of
knee injections persist to six months [17]. All previous
RCTs of corticosteroid injections for hip OA have included
a ‘placebo’ arm of injections of either local anaesthetic or
saline but only one has compared clinical effectiveness of
corticosteroid injection with best usual care [11].
There is, therefore, promising evidence to support the
use of intra-articular corticosteroid injection for patients
with hip OA, although current research is restricted to
small studies of more severely affected patients with only
short-term follow-up. The available studies therefore do
not reflect the true range of disease managed in primary
care, where patients may have less severe disease and are
more likely to have multi-morbidity which limits their
other treatment options. To ensure healthcare services
improve outcomes for patients we need to ensure there
is a robust and appropriate evidence-base to support
clinical decision making.
Objectives
The current protocol (version 6.0, 3 April 2018) is de-
scribed below. Key amendments to the protocol since
trial registration are highlighted with comments in
square brackets and described in detail, along with ra-
tionale for change, in Table 1.
Primary objective
The primary objective of this trial is:
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Table 1 Key Protocol Amendments since Trial registration
Protocol
Section
Original protocol Amended details Date of
Amendment
REC approval
Rationale for amendment
Secondary
objectives
To explore reasons for non-
participation in the study and percep-
tions of recruitment processes with
aim of identifying any modifiable bar-
riers to recruitment [To undertake only
if recruitment less than anticipated at
3 month review]
Objective removed May 2018 We could not to complete the
qualitative objective - to explore
reasons for non-adherence - due to
low recruitment to this qualitative
study of people who were eligible for
the trial but unwilling to participate.
Furthermore, we had identified key
modifiable issues to facilitate method
of recruitment relating to eligibility cri-
teria (see below) and recruitment
route (see ‘Progress of the trial’).
Inclusion
Criteria
Moderate-to-severe hip pain (a score
of four or more on a 0–10 numeric
rating scale (NRS)) on the day of
assessment
Moderate-to-severe hip pain (a score
of four or more on a 0–10 numeric
rating scale (NRS)) on average over
the last 2 weeks and current hip pain
rated as at least 1 out of 10 (on a 0–
10 NRS) on the day of assessment
September
2016
During the first 5 months of
recruitment we observed that, due to
the day-to day variability of osteoarth-
ritis symptoms, a number of potential
participants did not meet the eligibil-
ity criterion of pain of 4/10 on the day
of assessment.
Exclusion
Criteria
Any contraindications to the use of
1% lidocaine hydrochloride as listed in
Summary of Product Characteristics
(SPC) e.g. complete heart block,
hypovolaemia,
Any contraindications to the use of
1% lidocaine hydrochloride as listed in
Summary of Product Characteristics
(SPC) e.g. complete heart block,
hypovolaemia, porphyria
September
2016
A review of the summary of product
characteristics (SPC) for lidocaine
hydrochloride revealed a new
contraindication (porphyria). Porphyria
was added to the exclusion criteria as
part of an urgent safety measure and
subsequent amendment.
Receiving anticoagulants (warfarin,
dabigatran, rivaroxaban, apixaban or
low molecular weight heparin)
Receiving anticoagulants (warfarin,
dabigatran, rivaroxaban, apixaban or
low molecular weight heparin),
ritonavir or cobicistat
January 2017 It was noted in the MHRA Drug Safety
Update dated 14 December 2016
‘Cobicistat, ritonavir and
coadministration with a steroid: risk of
systemic corticosteroid adverse effects’
that coadministration of
corticosteroids, including intra-articular
triamcinolone, with an HIV-treatment-
boosting agent may increase the risk
of corticosteroid side-effects including
adrenal insufficiency, adrenal suppres-
sion and Cushing’s syndrome, due to
a pharmacokinetic interaction. Receiv-
ing cobicistat or ritonavir were added
to the exclusion criteria as part of an
urgent safety measure and subse-
quent amendment.
Sample Size To address the primary objective, the
analysis will be based on comparisons
of participants’ ‘average’ follow-up
pain NRS scores, based on a random
effects linear repeated-measures
model, with a ‘cluster’ size of 4 (denot-
ing 4 follow-up assessments) and a
postulated coefficient of 0.5. A sample
size of 232 will provide 90% power
(5% two-tailed significance) to detect
a minimum difference of 1.5 points in
mean pain NRS score (anticipated
baseline SD of pain scores = 4.5 points;
effect size of 0.33) between I1 and I2
across the 6-month follow-up period,
allowing for total of 15% loss to
follow-up. As our trial also evaluates I3
(against I1), we have three groups of
interest and hence need 348
participants.
To address the primary objective, the
analysis will be based on comparisons
of participants’ ‘average’ follow-up
pain NRS scores, based on a random
effects linear repeated-measures
model, with four follow-ups and pos-
tulated correlations of 0.5 for repeat-
measures and 0.2 for baseline-
outcome. A sample size of 136 (68 per
arm) provides 80% power (5% two-
tailed significance) to detect a mini-
mum difference of 1 point in mean
pain NRS score (anticipated SD of
about 2.5; effect size of 0.4) between
I1 and I2 across the 6-month follow-
up period, allowing for 15% loss to
follow-up. As the trial also evaluates I3
(against I1), there are three groups of
interest and hence 204 participants
are needed.
May 2018 The Data Monitoring Committee
noted poor recruitment and
suggested rerunning the sample size
calculations to ensure the original
sample size assumptions were still
valid. The observed baseline standard
deviation (SD) of the primary outcome
based on data collected from
participants recruited by this time
point (n = 65) was 1.7 (and the SD for
follow up scores was around 2.5) – i.e.
much lower than the SD of 4.5
expected before the start of
recruitment on which the original
sample size calculation was based. The
clinically important difference of 1.5
(originally stated) in the context of this
baseline SD would be ‘large’ (effect
size above 0.8). The clinically
important difference of 1.5 was
considered to be too large in relation
to the lower expected SD. The
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 To compare longitudinal pain scores over 6 months,
in people with hip OA, between those receiving an
ultrasound-guided intra-articular hip injection of
corticosteroid with 1% lidocaine hydrochloride plus
best current treatment with those receiving best
current treatment alone.
Secondary objectives
The secondary objectives of this trial are:
 To compare the clinical effectiveness of an
ultrasound-guided intra-articular hip injection of
corticosteroid and 1% lidocaine hydrochloride and
best current treatment with best current treatment
alone across a range of secondary outcome measures
including physical function, stiffness, patient global
impression of change, general health, sleep, self-
efficacy, and satisfaction with treatment
 To compare the effect of an ultrasound-guided in-
jection of corticosteroid and 1% lidocaine hydro-
chloride plus best current treatment with an
ultrasound-guided injection of 1% lidocaine hydro-
chloride plus best current treatment on pain, phys-
ical function, stiffness, patient global impression of
change, general health, sleep, self-efficacy, and satis-
faction with treatment
 To compare the cost-effectiveness of ultrasound-
guided intra-articular injection of corticosteroid and
1% lidocaine hydrochloride and best current
treatment with best current treatment alone over
6 months
 To explore in a linked qualitative study, the
acceptability to, and impact of, ultrasound-
guided intra-articular joint injection to patients
with hip OA
 To explore in a linked qualitative study, the
experiences of patients of living with hip OA
 To explore reasons for non-participation in the study
and perceptions of recruitment processes with aim of
identifying any modifiable barriers to recruitment (to
undertake only if recruitment less than anticipated at
3 month review). [Amended, see Table 1]
Methods
Trial design
The trial is a pragmatic, three-parallel group, single-blind,
superiority, randomised controlled trial in patients with
painful hip OA. The intervention arms are:
 best current treatment (intervention arm 1, I1)
 best current treatment plus ultrasound-guided intra-
articular hip injection of corticosteroid (triamcino-
lone acetonide 40 mg) and 1% lidocaine hydrochlor-
ide (intervention arm 2, I2)
 best current treatment plus ultrasound-guided intra-
articular hip injection of 1% lidocaine hydrochloride
alone (intervention arm 3, I3)
Table 1 Key Protocol Amendments since Trial registration (Continued)
Protocol
Section
Original protocol Amended details Date of
Amendment
REC approval
Rationale for amendment
clinically important difference for the
NRS-pain scale has taken different
values across studies; an absolute dif-
ference of 1 has been specified in
some studies (which would relate to a
“moderate” effect size (0.5) when the
SD is around 2; or, 0.4 in relation to
higher SD of 2.5 which is observed
across follow up time points). Hence,
we felt that a revised effect size of 0.4
is justifiable. Using this revised effect
size of 0.4 and revised power of 80%
(on the advice of the TSC), the sample
size was amended as described, and
was approved by the funder, TMC and
DMC.
Recruitment
period
The monthly target for recruitment
will be 20. A recruitment period of
18 months will therefore be required.
An amended recruitment period of
29 months is required to meet the
revised sample size (n = 204). The
monthly target for recruitment has
been adjusted from 20 to 10.
May 2018 During the first 18 months of trial
recruitment an average of 7 patients
per month were recruited.
Recruitment improved since greater
emphasis has been placed on
recruitment route 3 to an average of
10 per month. Recruitment period was
recalculated based on observed
recruitment and revised sample size.
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Participants with moderate-to-severe hip OA consult-
ing at musculoskeletal clinics at the primary-secondary
care interface and in secondary care or identified from a
Read Code search at participating General Practices are
randomised on an equal basis (1:1:1 ratio) to one of
these intervention arms. Follow-up data are gathered
from participants at 2 weeks, 2 months, 4 months and
6 months via postal questionnaires. The experience and
impact and perceptions of receiving an intra-articular hip
injection for hip OA compared to best current treatment
alone are explored in in-depth qualitative interviews in a
purposive sample of approximately 30 participants (n = 10
from each of the three arms of the trial).
Study setting
Participants are recruited from primary care referrals to
orthopaedics, rheumatology and two musculoskeletal Na-
tional Health Service (NHS) interface services in Stafford-
shire, UK. These services are variously staffed by GPs with
specialist musculoskeletal interests, extended-scope phys-
iotherapists, rehabilitation medicine specialists, rheuma-
tologists and orthopaedic surgeons. The musculoskeletal
hip clinics, where patients are screened, consented and
treated, take place at the two musculoskeletal interface
services in Staffordshire.
The research sites received local management ap-
proval, trial specific training covering the interventions
(with competency in delivery of the trial interventions
being confirmed) and trial administrative procedures,
and undertook sufficient research preparation (including
Good Clinical Practice (GCP) training) prior to the start
of recruitment into the trial.
Participants
The study population consists of participants with
moderate-severe pain attributable to hip OA. Diagnosis is
based on presenting symptoms and routine clinical history
and examination supported by radiographic evidence of
hip OA.
Inclusion criteria
1. Male or female aged ≥40 years
2. A clinical diagnosis of unilateral or bilateral hip OA,
and confirmed on plain radiography within the last
24 months
3. Moderate-to-severe hip pain (a score of four or
more on a 0–10 numeric rating scale (NRS)) on
average over the last 2 weeks and current hip pain
rated as at least 1 out of 10 (on a 0–10 NRS) on the
day of assessment [amended, see Table 1]
4. Symptom duration of episode of at least 6 weeks
5. Hip pain occurring on most days of the last month [18]
6. Informed written consent provided by the patient
Exclusion criteria
1. Hip pain due to other disorders (e.g. trochanteric bur-
sitis, avascular necrosis, pain referred from back).
2. Intra-articular corticosteroid injection into the af-
fected hip or ipsilateral trochanteric bursa injection
within the preceding 3 months.
3. Any previous surgery on the affected hip.
4. Clinical suspicion of local or systemic sepsis or
infection.
5. Current or previous infection of the affected hip.
6. Significant trauma to the affected hip requiring im-
mobilisation in the previous 3 months.
7. Unwillingness to undergo study interventions.
8. Unable to understand and complete self-report
questionnaires written (or spoken) in English.
9. Significant illness (known or suspected) including,
but not limited to:
• inflammatory joint disease (e.g. rheumatoid arthritis,
seronegative spondyloarthropathy (ankylosing spondylitis,
psoriatic arthritis, reactive arthritis, inflammatory-bowel
disease associated inflammatory arthritis)).
• polymyalgia rheumatica or other condition requiring
regular oral steroid use.
• malignancy (where malignancy is thought to be caus-
ing hip pain e.g. suspected bony metastases).
• any other severe medical illness which in the opinion
of the local Principal Investigator (PI)(or other authorised
clinical delegate) precludes trial participation.
10. Pregnant or lactating females.
11. Receiving anticoagulants (warfarin, dabigatran, riv-
aroxaban, apixaban or low molecular weight heparin), ri-
tonavir or cobicistat [Amended, see Table 1].
12. Any history of hypersensitivity to triamcinolone
acetonide or 1% lidocaine hydrochloride or any of their
excipients (1 N Hydrochloric Acid QS, 1 N Sodium Hy-
droxide QS, Benzyl alcohol. Polysorbate 80, Sodium car-
boxymethylcellulose and Sodium chloride).
13. Any contraindications to the use of 1% lidocaine
hydrochloride as listed in Summary of Product Charac-
teristics (SPC) e.g. complete heart block, hypovolaemia,
porphyria [Amended, see Table 1].
Patient identification
Potential participants are identified via three routes:
1. GP referrals of patients with hip pain into
participating NHS musculoskeletal services at two
locations. Local GPs are informed that the trial is
taking place and encouraged to refer patients whom
they feel may be eligible to participate. Pop-up elec-
tronic reminders are incorporated into GP elec-
tronic record systems to remind GPs if they enter a
code for hip pain or OA during a primary care con-
sultation. Patients are triaged into dedicated
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musculoskeletal hip research clinics and are sent
the Participant Information Leaflet (PIL) prior to
their appointment.
2. Patients who have not been directly booked or
triaged into the musculoskeletal hip clinic, but who
have been referred for management of hip OA to
other musculoskeletal, rheumatology and
orthopaedics clinics are also identified at their
initial appointment. Those deemed to be eligible
and interested are given a PIL by the treating
clinician.
3. The electronic records of GP practices in the local
clinical research network are searched to identify
patients consulting with hip pain in the last
12 months. This search is conducted periodically,
within small groups of local practices in order to
invite consulters with hip pain to the
musculoskeletal hip clinic. The search will generate
a list of NHS numbers which are screened so that
those individuals who have already been referred to
the musculoskeletal hip clinic can be excluded.
Those who have not already been referred into the
service are sent a PIL and a letter inviting them to
telephone the Keele Clinical Trials Unit (CTU) if
they are interested in attending the musculoskeletal
hip clinic. Those who telephone the CTU
administrator will receive a brief, provisional
eligibility screening. Those who are eligible at this
stage are made an appointment for the
musculoskeletal hip clinic.
Participant screening
Patients identified by routes 1 and 2 above will attend
for their routine clinic appointment, according to nor-
mal NHS clinical attendance procedures. For patients
identified by route 3, a brief, provisional eligibility screen
will have been carried out over the telephone by the
CTU administrator prior to the appointment being made
and a preliminary informed consent to ‘screening assess-
ment’ are taken prior to any eligibility assessment.
The clinical consultation is undertaken by the local PI
(or authorised delegate). In accordance with the UK
Clinical Trial Regulations, a patient’s eligibility to partici-
pate in the trial is the responsibility of a medically quali-
fied doctor. All patients presenting with painful hip OA
are considered for inclusion and an Eligibility Screening
Form completed.
Patients who have not had a hip radiograph in the past
24 months will undergo radiography as part of eligibility
screening. For patients identified via routes 1 and 2 this
is in line with usual clinical practice and normal proce-
dures in the musculoskeletal clinic. For patients identi-
fied via route 3, radiographs are obtained as a study
procedure if they have not had a radiograph performed
in the last 24 months. The preliminary consent to
‘screening assessment’ is performed prior to these radio-
graphs being obtained.
Anteroposterior (AP) pelvis and lateral oblique views
are obtained as detailed below.
AP pelvis: The patient lies supine on the table with
their legs extended and their head resting on a pillow.
The median sagittal plane (MSP) is at 90 degrees to the
table top and the anterior superior iliac spines (ASISs)
are at equal distance from the table-top. The arms are
raised onto the pillow. The legs are slightly internally ro-
tated to bring the necks of femora parallel to the
table-top. Gonad protection is applied if appropriate.
The beam is centred in the midline, midway between the
ASIS and the upper border of the symphysis pubis.
Lateral oblique hip: From the initial AP pelvis position
the patient is rotated laterally through 45 degrees onto
the side under examination and supported in this pos-
ition with foam pads. The knee and hip are flexed and
externally rotated to bring the lateral aspect of the thigh
in contact with the table-top. The arms are rested on the
pillow. Gonad protection is applied. The beam is centred
to the femoral pulse.
Recruitment and consent
Eligible patients who are interested in trial participation
are invited by the local PI (or authorised delegate) to see
a researcher or research assistant who will explain the
trial in full. The researcher or research assistant will
have received appropriate training and be authorised on
the site trial delegation log. Patients are able to ask ques-
tions about study involvement. Those who remain inter-
ested in participation after seeing the researcher are
consented by a researcher, complete baseline data collec-
tion, undergo randomisation and receive the interven-
tion during the same clinic visit.
Documented reasons for ineligibility or declining par-
ticipation are monitored by the Keele CTU as part of a
regular review of recruitment progress.
Patients who decline assessment of eligibility, who are
either ineligible to participate or who do not wish to par-
ticipate are thanked for their attendance and instructed
to consult their GP should their symptoms continue
(route 3) or managed as per usual care (routes 1 and 2).
Randomisation
Allocation
Participants are randomised by an administrator in
clinic after consent, baseline data collection and de-
livery of best current treatment in a 1:1:1 ratio, via
the Keele CTU’s web-based randomisation service.
This is a secure web-based randomisation system with
emergency telephone back-up. The randomisation se-
quence is computer-generated. Once randomised, the
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authorised staff member is notified of the participant’s
treatment allocation.
Allocation concealment
Concealment of the allocation process is ensured
through the remote computer-generation of the ran-
domisation sequence and web-based interface including
entry of participant details and necessary consent prior
to a unique participant identification number being gen-
erated and disclosure of treatment allocation.
Sequence generation
Blocking (of individual participants) is used as the unit
randomisation method to ensure similar numbers of par-
ticipants are allocated to the three treatment arms. Ran-
dom permuted block sizes of 3 and 6 are used to give 96
possible randomisation sequences (for each unit of ran-
domisation) with equal chance (determined using a
computer-generated random function). The sequence is
held within the computer system and not known to re-
searchers/administrators so as to preserve concealment
integrity, and hence comparability of participant alloca-
tion between study arms.
Blinding
Participants and clinicians will not be blind to allocation
to best current treatment only (I1) or injection (I2 or I3).
However, for those participants randomised to either of
the two injection arms, participants are blind to the exact
nature of the injection (triamcinolone acetonide plus 1%
lidocaine hydrochloride or 1% lidocaine hydrochloride
alone) to ensure the validity of the 1% lidocaine hydro-
chloride injection as a credible placebo. The Research
Nurse will remain blind to treatment allocation to enable
the nurse who conducts Minimum Data Collection
(MDC) to remain unaware of allocation. The statistician
will also be blind to treatment allocation. The qualitative
researcher is blind to injection group allocation.
Those injected are informed to carry a trial informa-
tion card at all times during the first 2 months and to
present it to medical staff should they be admitted to
hospital during their participatory period (6 months).
24-h emergency unblinding is available.
Interventions
The interventions are delivered in the context of a ‘one--
stop’ clinic where assessment, baseline data collection,
randomisation and intervention all occur within the
same visit.
If bilateral symptoms are present, the hip with the
most severe symptoms according to the participant is
treated. In the event that both hips are equally affected,
the participant is asked to choose which hip to treat.
The contralateral hip may be treated in accordance with
local guidelines (excluding intra-articular hip injection).
Any treatment to the contralateral hip does not consti-
tute trial treatment and is captured through the partici-
pant follow-up questionnaires.
Intervention arm 1 (I1): Best current treatment
Participants randomised to this intervention receive
written information (the Arthritis Research UK Osteo-
arthritis leaflet [19] and a bespoke HIT trial leaflet on
exercise and functional activities), and personalised ad-
vice and information about weight loss, exercise, foot-
wear, walking aids and optimising pain management,
delivered by the PI (or authorised delegate) within the
clinic visit.
Intervention arm 2 (I2): Best current treatment plus intra-
articular injection of corticosteroid plus lidocaine
Participants randomised to this intervention receive best
current treatment as I1 plus one ultrasound-guided
intra-articular injection of 40 mg triamcinolone aceto-
nide and 4mls 1% lidocaine hydrochloride into the hip.
Both triamcinolone acetonide 40 mg/ml sterile, aque-
ous suspension and 1% lidocaine hydrochloride 10 mg/
ml solution for injection are prepared and handled in
line with manufacturer’s recommendations as outlined
and in accordance with the SPC.
A disposable 25G needle and syringe is be used for re-
gional anaesthesia of the skin and superficial soft tissues
and a 22G spinal needle and syringe is used for regional
anaethesia of deeper soft tissues and intra-articular
injection.
The following technique is observed when applying
intra-articular injections:
Preparation for the injection includes: LOGIQ ultra-
sound system with a 1-4 MHz curvilinear transducer
(GE Healthcare, Hatfield, England); disposable sterile
transducer sheath; disposable 25G needle for regional an-
aesthesia of skin and superficial soft tissues, and dispos-
able 22G spinal needle for regional anaesthesia of deeper
soft tissues and intra-articular injection. Three syringes
are prepared containing: 3mls 1% lidocaine hydrochloride;
4mls 1% lidocaine hydrochloride and 1 ml 40 mg triam-
cinolone acetonide.
A sterile aseptic technique is observed. The participant
lies supine with legs extended into a neutral position of
comfort. The skin is cleaned with chlorhexidine 0.5% so-
lution. The transducer is covered with gel and a sterile
sheath. Sterile gel is applied to the external surface of
the sheath. The anterior capsule of the hip joint is lo-
cated using ultrasound guidance and 3mls 1% lidocaine
hydrochloride is introduced to the overlying skin and
superficial soft tissues using a 25 g needle. A 22G spinal
needle will then be inserted, observing its route in
real-time by ultrasound, until its tip is seen to enter the
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anterior joint capsule. 1 ml of 1% lidocaine hydrochlor-
ide is injected into the hip to confirm correct placement
and 40 mg of triamcinolone acetonide (1 ml volume)
with a further 3mls of 1% lidocaine hydrochloride is
injected showing distension of the capsule by the fluid
under ultrasound (total intracapsular volume 5mls). The
needle is withdrawn, haemostasis ensured and a dressing
applied over the injection site. Participant should be ad-
vised to wait 15 min following injection or alternatively
ensure that they are accompanied by a responsible adult
for that time. Participants are advised to observe min-
imal weight-bearing for 24 h following the injection, and
not to drive for 24 h.
It is understood that there may be slight variations to
the described technique due to previous training. All in-
jectors will undergo trial-specific training in injection
technique and there is a standard operating procedure
in place.
Intervention arm 3 (I3): Best current treatment plus intra-
articular injection of lidocaine
Participants randomised to this intervention will receive
one ultrasound guided intra-articular injection of 5mls
1% lidocaine hydrochloride into the hip plus best current
treatment.
The injection procedure is conducted as described
above (I2) with two exceptions. Three syringes are pre-
pared containing: 3mls 1% lidocaine hydrochloride; 4mls
1% lidocaine hydrochloride and 1mls 1% lidocaine
hydrochloride. 1 ml of 1% lidocaine hydrochloride is
injected into the hip to confirm correct placement and a
further 4mls of 1% lidocaine hydrochloride is then
injected showing distension of the capsule by the fluid
under ultrasound (total intracapsular volume 5mls).
Injections are delivered by clinicians (2 Consultant
rheumatologists, 2 Extended Scope Physiotherapists and
one Consultant musculoskeletal sonographer) who are
fully trained in the technique and work in the musculo-
skeletal services. Since musculoskeletal ultrasound is
highly operator-dependent and relies on robust training
with direct supervision to gain clinical competency, cli-
nicians performing US-guided injections have extensive
clinical experience performing US guided injections and
will have their competency assessed by a Consultant
musculoskeletal sonographer prior to commencement of
the trial.
Crossover and post-trial care
Participants cannot cross over from one arm of the trial
to the other. If a participant declines injection after ran-
domisation, this is recorded as a protocol deviation and
the participant’s data included in the Intention-to-Treat
(ITT) analysis. Similarly, if a participant in the best
current treatment arm (I1) of the trial receives an
injection as part of standard care they are managed as a
protocol deviation and included in ITT analysis.
Participants’ clinical care after the ‘one-stop’ research
clinic returns to usual NHS healthcare.
Outcomes
The primary endpoint is patient-reported hip pain inten-
sity over the whole of 6-months follow-up (through re-
peated measures at 2 weeks, 2 months, 4 months and
6 months) post-randomisation).
Secondary endpoints are at each of the individual
follow-up points (i.e. 2 weeks, 2 months, 4 months and
6 months post-randomisation).
Primary outcome measure
Patient-reported hip pain intensity measured using a 0–
10 Pain Numeric Rating Scale for current hip pain (hip
pain today) [20].
Secondary outcome measures
The secondary outcomes include pain, stiffness and every-
day physical function (Western Ontario and McMaster
University Arthritis Index (WOMAC v 3.1)) [21], partici-
pants’ self-reported global impression of change [22], gen-
eral health (SF-12, EQ-5D-5 L) [23, 24], sleep disturbance
(adapted from Dawson et al. [25]), pain self-efficacy [26],
illness perceptions [27], maintenance of and return to de-
sired activities including work and social life, healthcare
utilisation including medication use and participant in-
curred cost, treatments received (including referral for
surgery and analgesia), participants’ satisfaction with treat-
ment, work (employment status, performance, absence),
joint replacement surgery (National Joint Register). Table 2
summarises the content of the participant questionnaires.
Adverse events
Triamcinolone acetonide and 1% lidocaine hydrochlor-
ide have specific licenses for the treatment of osteoar-
throsis (osteoarthritis) and regional anaesthesia
specifically and have been widely used for many years
in standard practice in both primary and secondary
care and have very well-established and understood
safety profiles [21]. They are being used in accordance
with the guidance given in the British National Formu-
lary (BNF) and Map of Medicine guidance for injection
in hip OA [9, 10]. The incidence of adverse predictable
undesirable side-effects associated with the use of corti-
costeroids correlates with the relative potency of the
drug, dosage, and timing of administration and dur-
ation of treatment, and therefore based on the dosage
to be used in this study, there is no requirement to rec-
ord non-serious adverse events beyond normal clinical
practice. The following events will not be recorded as
Serious Adverse Events (SAEs) within this trial:
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Hospitalisation for:
 Routine treatment or monitoring of hip OA
associated with any deterioration in condition
 Treatment which is elective or pre-planned, for a
pre-existing condition not associated with any de-
terioration in condition
 Prolongation of hospitalisation not associated with
an adverse event
 Admission to hospital or other institution for
general care, not associated with any deterioration in
condition
 Treatment on an emergency, outpatient basis for an
event not fulfilling any of the definitions for serious
as given above and not resulting in hospital
admission
Where a SAE or Suspected Unexpected Serious Ad-
verse Reaction (SUSAR) occurs, reporting procedures
are in place that are in accordance with good clinical
practice guidance and the requirements specified by the
Medicines and Healthcare products Regulatory Agency
(MHRA). All SAEs are considered by the external moni-
toring committees.
Data collection
All participants enrolled in the trial are asked to complete
a paper questionnaire at the baseline clinic appointment
Table 2 Participant Questionnaire Content
Visits Baseline 2-week 2-month 4-month 6-month
Baseline measures
Demographics (date of birth, gender) ✓ ✓ ✓ ✓ ✓
Demographics (marital status) ✓
Hip pain questions: uni/bilateral, duration ✓
Previous hip injection ✓
Participant treatment preference and expectations ✓
Comorbidity ✓
Self-reported height and weight (BMI) ✓ ✓
Other musculoskeletal pain (Body manikin) [22] ✓
Anxiety and Depression – GAD and PHQ8 [23, 24] ✓
Primary Outcome measure
Pain - Numerical Rating Scale score for current pain [20] ✓ ✓ ✓ ✓ ✓
Secondary outcome measures
Function - Western Ontario and McMaster University
Arthritis Index (WOMAC v3.1) [32]
✓ ✓ ✓ ✓
Participant’ self-reported global impression of change [33] ✓ ✓ ✓ ✓
General health (SF-12) [34] ✓ ✓ ✓ ✓
Sleep disturbance (Likert type scale, adapted from Dawson et al. [35]) ✓ ✓ ✓ ✓
Pain self-efficacy [36] ✓ ✓ ✓ ✓
Modified Brief Illness Perceptions Questionnaire [37] ✓ ✓ ✓
Satisfaction and experience ✓ ✓
Health Economic Outcomes
Health status - EQ5D-5 L [38] ✓ ✓ ✓ ✓ ✓
Employment status ✓ ✓
Performance at work ✓ ✓ ✓
Absenteeism from work ✓ ✓ ✓
Health care utilisation ✓ ✓
Participant -incurred costs ✓ ✓
Process Data
Other hip injections received ✓ ✓
Self-reported adverse events ✓ ✓
Adherence to best current treatment advice ✓ ✓ ✓
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and a posted questionnaire after 2 weeks, 2 months,
4 months and 6 months. Questionnaires will capture data
on all outcome measures (Table 2).
Baseline data collection includes: demographics (date of
birth, gender, marital status); hip pain questions: uni/bilat-
eral, duration; previous hip injection; participant treatment
preference and expectations; comorbidity; self-reported
height and weight (Body Mass Index - BMI), other muscu-
loskeletal pain (Body manikin) [22] and anxiety and depres-
sion – Generalised Anxiety Disorder (GAD) and Patient
Health Questionnaire 8 [23, 24].
For participants receiving I2 and I3, bilateral ultra-
sound images are stored, and scored on the presence or
absence of synovitis and effusion. Participants are also
asked which injection they think they received.
Non-responders to the 2-week follow-up postal ques-
tionnaire are sent a repeat questionnaire and PIL after 10
calendar days. Those who do not respond to the repeat
questionnaire within 10 days are telephoned by the Re-
search Nurse (who will remain blind to group allocation),
in order to try to capture key primary outcome data and
to minimise missing data. A postal MDC form is mailed
to the participant if the participant has not been contacted
after 5 phone-call attempts.
At other follow-up time-points, non-responders are sent
a reminder postcard after 10 days. Those who do not re-
spond to the reminder postcard are sent a repeat ques-
tionnaire and Participant Information Sheet with a further
covering letter after a further 10 days. Non-responders to
the repeat questionnaire are telephoned by the Research
Nurse (blind to treatment allocation) 10 days later. A pos-
tal MDC form are mailed to the participant if the partici-
pant has not been contacted after 5 phone-call attempts.
The flow of events as participants proceed through the
trial is outlined in (Fig. 1) and the timing of key events
outlined in Table 3.
Sample size
To address the objectives of the trial, 204 participants (68
in each arm) need to be recruited over a 29-month period
[amended since trial registration, see Table 1 and ‘Progress
of trial’]. To address the primary objective, the analysis will
be based on comparisons of participants’ ‘average’
follow-up pain NRS scores, based on a random effects
Fig. 1 Flow of participants through trial
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linear repeated-measures model, with four follow-ups and
postulated correlations of 0.5 for repeat-measures and 0.2
for baseline-outcome. A sample size of 136 (68 per arm)
provides 80% power (5% two-tailed significance) to detect
a minimum difference of 1 point in mean pain NRS score
(anticipated SD of about 2.5; effect size of 0.4) between I1
and I2 across the 6-month follow-up period, allowing for
15% loss to follow-up. As the trial also evaluates I3
(against I1), there are three groups of interest and hence
204 participants are needed.
Statistical methods
The analysis will be undertaken according to an analysis
plan agreed with the TSC and DMC, incorporating statis-
tical analysis, health economics and qualitative analysis.
The main statistical analysis is based on reporting
guidelines for the design and conduct of parallel-arm tri-
als [25]. The main treatment analysis will be conducted
blinded to treatment allocation and will be analysed on
an intention to treat (ITT) approach with all randomised
participants retaining their original randomised group.
Estimation through linear mixed modelling takes ac-
count of missing data (under the missing at random
(MAR) missingness assumption). Analysis will be ad-
justed for baseline covariates (pain, age and gender).
Additional sensitivity analysis will address the robustness
of the findings to deviation from the MAR assumption –
specifically through considering plausible ‘missing not at
random’ (MNAR) scenarios.
Key baseline characteristics of participants in the three
treatment groups will be presented to illustrate compar-
ability. The linear mixed model will be used to derive es-
timates of ‘average’ pain across the four time points
(thus reflecting summary pain assessment across the full
follow-up period) as well as estimates of pain at each
time point (by modelling the interaction of group by
time). In each evaluation, a random-slope model will be
preferred (to a random-intercept model) if the
goodness-of-fit of the model is significantly improved
through time-projected random-slope specification.
Statistical significance is at the 5% probability level
(two-tailed). The collection of data and statistical ana-
lysis will be performed blinded to treatment allocation.
The primary clinical evaluation will be a comparison of
pain NRS scores over the 6-month follow-up period
(with repeated measures at 2 weeks and 2, 4 and
6 months) between those treated with best current treat-
ment plus corticosteroid and lidocaine injection, and
those treated with best current treatment alone.
The secondary clinical evaluations will include: evalu-
ation of pain NRS score differences between groups at
each of the individual time points (2 weeks, 2 months,
4 months and 6 months) as well as between-group com-
parison of secondary outcome measures over the
6-month follow-up period. Mixed models for repeated
measures (MMRM) will be through linear-regression in
respect of numerical outcomes, and logistic-regression
in relation to categorical outcome measures. A number
of follow-up data are anticipated to be retrieved through
minimum data collection, and therefore we will use mul-
tiple imputation (MI) using chain equations [26] to im-
pute missing secondary outcome data – the prediction
models will include baseline variables and the (primary)
pain outcome measure as predictors. MI, similar to
mixed modelling, estimates effect on the basis of an
MAR missingness mechanism. Estimation of the primary
outcome measure based on MI evaluation will be carried
out as a sensitivity analysis of the main MMRM analysis.
Table 3 Participant Timeline
Visits Pre-
Baseline
Baseline
Day 0
Randomisation
Day 0
Intervention
Day 0
2-week
follow-up
2-month
follow-up
4 month
follow-up
6-month
follow-up
Duration of Intervention
Events
Brief telephone screening (identified via route 3) ✓
Consent to eligibility screening assessment
(route 3)
✓
Eligibility Screening ✓
Full informed consent by researcher/ research
assistant
✓
Randomisation ✓
Participant Questionnaire (see Table 1) ✓ ✓ ✓ ✓ ✓
Web-based randomisation ✓
Administration of study intervention ✓
SAE reporting ✓ ✓ ✓ ✓ ✓
Expedited reporting (< 24 h) of Suspected
Unexpected Serious Adverse Reactions (SUSARs)
On going
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In addition, an MI analysis incorporating plausible devi-
ations from ignorable missingness will be considered in
respect of sensitivity analysis of the primary outcome to
MNAR missing data.
The primary analyses will be adjusted for the following
baseline covariates: pain score, age and gender (and
EQ5D for health economic evaluation). Estimates of
clinical effect will be shown as mean (SDs) differences
(for numerical outcomes) and odds ratios (for dichotom-
ous outcomes), with 95% confidence intervals (CI). As
previously stated, regression analysis will be based on a
linear model for numerical outcomes and binary logistic
model for dichotomous outcomes with a random-effects
component being added to the model for repeated mea-
sures data, to take into account the intra-cluster correl-
ation. To help in interpreting the size of the estimated
clinical effect for the between-group difference in pain
(overall and at individual time points) we will calculate
the standardised mean difference (‘effect size’) which is
the ratio of the estimated mean difference to the stand-
ard deviation of pain scores in the total randomised
population. For all evaluations of the primary outcome,
we will present mean and 95% confidence interval esti-
mates. The number needed to treat (NNT) with 95% CI
will be calculated in respect of the comparison between
best current treatment plus corticosteroid and 1% lido-
caine hydrochloride injection and best current treatment
alone [27].
Exploratory subgroup analysis will include evaluation
of variables such as
 Participants’ expectations regarding treatment
response
 Participants’ treatment preference
 Illness perceptions
 Adherence to best current treatment
 Presence of synovitis or effusion on ultrasound
 BMI
 Duration of symptoms
 Severity of symptoms
Economic evaluation
The health economic analysis will determine the
cost-effectiveness of intra-articular corticosteroid injec-
tion for hip OA and best current treatment compared
with best current treatment alone. A cost-consequence
analysis will initially be reported, describing all import-
ant results relating to costs and outcomes. An incre-
mental cost-utility analysis will be undertaken using
participant responses to the EuroQoL EQ-5D-5 L ques-
tionnaire at baseline and each follow-up time-point, to
calculate the cost per additional Quality-Adjusted Life
Year (QALY) gained. The base-case analysis will adopt
an NHS perspective and will include costs of the
intervention and best current treatment, and other hip
OA-specific health care utilisation. These may include
primary care consultations, prescriptions, secondary
care contacts and over-the-counter purchases by partic-
ipants. Information on health care resource use and
work absenteeism will be collected from participant
questionnaires at six months. The robustness of the re-
sults will be explored using sensitivity analysis. Uncer-
tainty in the confidence to be placed on the results of
the economic analysis will be explored conducting a
probabilistic sensitivity analysis to estimate cost effect-
iveness acceptability curves. Results from a broader so-
cietal perspective will also be presented, and will
include participant-incurred and productivity costs in
addition to heath care costs.
Qualitative study
A sample of responders to the 2-month follow up question-
naire are invited for interview to ask them about their expe-
riences of participating in the trial and of living with hip
osteoarthritis. Participants are sampled on a range of char-
acteristics including age, gender, pain score and satisfaction
with treatment. Participants are asked to complete and re-
turn a reply slip should they be interested in taking part in
the interview. Interested participants are contacted by tele-
phone to arrange a convenient time for the interview. In-
formed consent is taken prior to interview. Interviews are
conducted either over the telephone or face-to-face de-
pending on the participant’s preference. Recruitment is on-
going throughout the trial in phased batches.
Qualitative analysis
Data will be stored, and analysis managed, using NVivo
software. All interviews are audio-recorded and fully
transcribed verbatim and anonymised. An inductive ap-
proach will be taken to the analysis. Analysis is on-going
from the first data collection time-point; the data is ana-
lysed thematically and a coding framework developed in-
corporating emergent themes. The data will undergo
repeated comparisons through coding, recoding and
memo writing in order to generate themes and concepts
[28, 29], drawing on recognised techniques including the
scrutiny of deviant cases, and checking for confirmatory
or challenging evidence within the dataset [30]. Initial
qualitative data analysis will be undertaken blind to the
clinical trial results to facilitate an interpretive and in-
ductive approach [31].
Patient and public involvement and engagement (PPIE)
This study was discussed with our large and active PPIE
group prior to the funding submission. The group iden-
tified the importance of developing the research base for
treatments that may provide an alternative to oral anal-
gesia and that are less invasive than surgery. The group
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informed the design of the best current treatment inter-
vention, as an active treatment arm involving advice on
exercise and weight loss. The group have also piloted
the time taken to complete baseline data collection and
advised on content of the PIL and best current treat-
ment information leaflets. The PPIE group will continue
to work with the research team throughout the trial (for
example in advising the dissemination plan).
Trial organisation and monitoring
The Trial Steering Committee met prior to ethics appli-
cation in order to agree the final protocol, and at agreed
time intervals over the course of the pilot trial. An inde-
pendent Data Monitoring Committee (DMC) approved
the protocol and reviews the safety of the trial. Detailed
reports focusing on interim safety, recruitment and re-
tention are prepared by Keele CTU at approximately 6
monthly intervals. All data collection, database design,
data input and cleaning, as well as trial oversight proce-
dures, are in line with the standard operating procedures
of the Keele CTU and the conditions of the grant. Data
is centrally monitored for quality and completeness by
Keele CTU.
Data confidentiality and archiving
All information collected during the course of the trial is
kept strictly confidential. Information is held securely on
paper and managed electronically by Keele University
through Keele CTU. Keele CTU comply with all aspects
of the 1998 Data Protection Act. If a participant with-
draws consent from trial intervention and/or further col-
lection of data, their data will remain on file and is
included in the final study analysis. At the end of the
trial, data will be securely archived in line with the Spon-
sor’s procedures for a minimum of 5 years. Data held by
Keele CTU will be archived in the designated Keele
CTU archive facility and site data and documents will be
archived at the participating sites. Following authorisa-
tion from the Sponsor, arrangements for confidential de-
struction will then be made.
Progress of the trial
Recruitment commenced in January 2016. Unfortu-
nately, review of recruitment 3–6 months into the trial
revealed that recruitment was sub-optimal and less than
50% of that predicted. Two key amendments were made
(detailed in Table 1).
First on 19th August 2016 the eligibility criteria were
amended. Criterion 3 was originally ‘Moderate-to-severe
hip pain (a score of four or more on a 0-10 numeric rating
scale (NRS)) on the day of assessment’. During the first
5 months of recruitment we observed that, due to the
day-to day variability of osteoarthritis symptoms, a num-
ber of potential participants did not meet the eligibility
criteria of pain of 4/10 on the day of assessment. The TSC
suggested amending the criterion to ‘moderate to severe
hip pain (a score of four or more on a 0-10 numeric rating
scale (NRS)) on average over the last two weeks and
current hip pain rated as at least one out of 10 (on a 0-10
NRS) on the day of assessment’. This amendment was ap-
proved by the DMC and Research Ethics Committee
(REC). Forty-eight participants had been recruited at the
time of this amendment.
Second, in March 2017, the Data Monitoring Commit-
tee noted poor recruitment and suggested rerunning the
sample size calculations to ensure the original sample
size assumptions were still valid. The observed baseline
standard deviation (SD) of the primary outcome based
on data collected from participants recruited by this
time point (n = 65) was 1.7 (and the SD for follow up
scores is around 2.5) – i.e. much lower than the SD of
4.5 expected before the start of recruitment on which
the original sample size calculation was based. The clin-
ically important difference of 1.5 (originally stated) in
the context of this baseline SD would be ‘large’ (effect
size above 0.8). The clinically important difference of 1.5
was considered to be too large in relation to the lower
expected SD. The clinically important difference for the
NRS-pain scale has taken different values across studies;
an absolute difference of 1 has been specified in some
studies (which would relate to a “moderate” effect size
(0.5) when the SD is around 2; or, 0.4 in relation to
higher SD of 2.5 which is observed across follow up time
points). Hence, we felt that a revised effect size of 0.4 is
justifiable. Using this revised effect size of 0.4 and re-
vised power of 80% (on the advice of the TSC), the sam-
ple size was amended as described under ‘sample size’
heading, and was approved by the funder, TMC and
DMC. A funded extension was requested, to extend re-
cruitment from 18 months to 29 months, and approved
in November 2017.
We removed a second qualitative objective to explore
reasons for non-participation in the trial, to address any
modifiable barriers to recruitment. This was in part due to
limited capacity within the research team and low recruit-
ment to this qualitative study of people who were eligible
for the trial but unwilling to participate. All amendments
have received ethical approval.
Recruitment via Route 3 commenced 12 months into
recruitment and was noted to be more successful and be-
came the principle route of recruitment from July 2017.
Discussion
This paper describes the design of pragmatic randomised
trial which investigates the comparative clinical and cost
effectiveness of corticosteroid injections in reducing pain
in people with hip OA. A number of issues have been
addressed in the design of this trial.
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As the majority of patients with hip OA are managed
exclusively in primary care, it is important that the evi-
dence base for recommended interventions is suitable
for patients treated in this setting, especially at a time
when clinical commissioning groups in the UK are rede-
signing NHS clinical pathways. The study participants in
the existing five RCTs which have evaluated the effec-
tiveness of corticosteroid intra-articular injections re-
cruited participants from secondary care and are unlikely
to be representative of the wider primary care population.
Furthermore, three performed injections under flu-
oroscopic guidance which is not available in primary care
[13, 14, 16].
Eligibility criteria were defined to recruit a representa-
tive primary care population of moderate to severe hip
OA patients, protect patient safety and also to ensure
maximum generalisability of the results to primary care.
We deliberately did not exclude patients who were con-
sidered by clinicians to be eligible for onward referral for
surgery. This decision was taken on the advice of our
TSC, and particularly two lay members of the commit-
tee, who felt it was important that patients with more
severe OA should still be offered choice of non-surgical
interventions.
Whilst conducting the trial in a setting that is very close
to primary care is crucial to our research question and to
optimizing the generalisability of the findings, we recog-
nised the need to maximise recruitment and achieve real-
istic recruitment targets. Recruitment to this trial within
the first 5 months was lower than half that expected and
amendments to the study eligibility criteria and recruit-
ment routes are addressing this.
In summary, this paper describes the rationale and de-
sign for a randomised pragmatic trial that aims to deter-
mine the clinical and cost effectiveness of ultrasound
guided intra-articular corticosteroid injections in hip
OA. The proposed trial will make an important contri-
bution to the evidence base available to support effective
conservative management of hip OA in primary care
and will inform both patient management and future re-
search for treatment options for hip OA.
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